BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that David Stack, President and Chief Executive Officer of Pacira Pharmaceuticals, has joined Amarin's Board of Directors as an independent director effective December 10, 2012.
Mr. Stack has more than 25 years of successful pharmaceutical industry experience. Beyond his current role as President, Chief Executive Officer and Director of Pacira Pharmaceuticals, Mr. Stack is also a Managing Director at MPM Capital, and Founding Partner of Stack Pharmaceuticals, Inc. Mr. Stack's extensive experience includes, from 2001 to 2004, President, CEO and a Director of The Medicines Company where he was recognized as the Ernst and Young Entrepreneur of the Year in 2003. Prior to The Medicines Company, Mr. Stack was the President and General Manager of Innovex Inc., Vice President of Business Development and Marketing for Immunomedics, Inc., and Director of Business Development and Planning for Infectious Disease, Oncology and Virology of Roche Laboratories. Mr. Stack holds a degree in pharmacy from Albany College and a BS in biology from Siena College where he is currently a Trustee. Mr. Stack is a Director of Medivo, Inc. and PepTx, Inc.
"The addition of Dave Stack further expands on the operational experience of the Amarin Board of Directors and enhances the Board's outstanding talent and pharmaceutical industry expertise," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Dave's insights will be valuable as we continue toward the Vascepa commercial launch early in the first quarter of 2013."
"Amarin has a unique asset in Vascepa, a great management team and strong momentum as it seeks to lead the next generation of lipid management," stated Mr. Stack. "I look forward to working with Amarin's Board and management team as the company capitalizes on such a significant market opportunity."
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817
This press release contains forward-looking statements, including statements about the timing of a commercial launch of Vascepa and preparations for commercial launch. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include risks associated with the launch of a new pharmaceutical product, such as adequacy of supply and compliance with regulatory requirements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Amarin contact information: Stephen D. Schultz Investor Relations and Corporate Communications Amarin Corporation In U.S.: +1 (908) 719-1315 firstname.lastname@example.org